Get notified when SLS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Going Concern (new) — Company disclosed substantial doubt about ability to continue as going concern due to insufficient cash for next 12 months.
SELLAS nears REGAL trial readout (78 of 80 events) but discloses going concern warning
Filed May 12, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~1 min read
Key Changes
-
high
Company disclosed substantial doubt about ability to continue as going concern, stating $28.4M cash insufficient for 12-month operations. No new financing announced to address shortfall.
MD&A: Liquidity verify on EDGAR → -
high
REGAL trial reached 78 of 80 required events as of May 11, 2026, signaling final analysis imminent. Company remains blinded to efficacy data; no statistical penalty incurred from one-time event count disclosure.
MD&A: Clinical Development verify on EDGAR → -
high
Arbitration hearing against partner 3D Medicines held January 2026 over $13M in disputed milestone payments; final determination pending. No milestone payments received in past 12+ months despite ongoing dispute.
Legal Proceedings verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade SLS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify